These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793 [TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039 [TBL] [Abstract][Full Text] [Related]
5. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Aletaha D; Maa JF; Chen S; Park SH; Nicholls D; Florentinus S; Furtner D; Smolen JS Ann Rheum Dis; 2019 Dec; 78(12):1609-1615. PubMed ID: 31434637 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617 [TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258 [TBL] [Abstract][Full Text] [Related]
9. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242 [TBL] [Abstract][Full Text] [Related]
10. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study. Damjanov N; Tlustochowicz M; Aelion J; Greenwald M; Diehl A; Bhattacharya I; Peeva E; Menon S; Gourley I J Rheumatol; 2016 Dec; 43(12):2094-2100. PubMed ID: 27909139 [TBL] [Abstract][Full Text] [Related]
12. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357 [TBL] [Abstract][Full Text] [Related]
13. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260 [TBL] [Abstract][Full Text] [Related]
14. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. Šenolt L; Leszczynski P; Dokoupilová E; Göthberg M; Valencia X; Hansen BB; Cañete JD Arthritis Rheumatol; 2015 Jun; 67(6):1438-48. PubMed ID: 25707477 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270 [TBL] [Abstract][Full Text] [Related]
17. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis. Dokoupilová E; Aelion J; Takeuchi T; Malavolta N; Sfikakis PP; Wang Y; Rohrer S; Richards HB Scand J Rheumatol; 2018 Jul; 47(4):276-281. PubMed ID: 29458278 [TBL] [Abstract][Full Text] [Related]
18. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial]. Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669 [TBL] [Abstract][Full Text] [Related]
20. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]